BioArctic (DB:B9A) - Stock Price, News & Analysis

B9A Stock Overview

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden.

B9A fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	6/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 74.8% below our estimate of its fair value

Earnings are forecast to grow 48.19% per year

Became profitable this year

Analysts in good agreement that stock price will rise by 89.1%

Risk Analysis

No risks detected for B9A from our risk checks.

BioArctic AB (publ) Competitors

Biotest

XTRA:BIO3

€1.4b

Dermapharm Holding

XTRA:DMP

€1.7b

Kiniksa Pharmaceuticals

NasdaqGS:KNSA

US$1.2b

Bavarian Nordic

CPSE:BAVA

kr.11.2b

Price History & Performance

Summary of all time highs, changes and price drops for BioArctic
Historical stock prices
Current Share Price	kr16.63
52 Week High	kr32.06
52 Week Low	kr15.79
Beta	-0.17
1 Month Change	-10.01%
3 Month Change	-16.85%
1 Year Change	-25.02%
3 Year Change	89.19%
5 Year Change	127.81%
Change since IPO	112.85%

Recent updates

Shareholder Returns

	B9A	DE Biotechs	DE Market
7D	-0.5%	-0.2%	0.5%
1Y	-25.0%	-22.8%	1.3%

Return vs Industry: B9A underperformed the German Biotechs industry which returned -23% over the past year.

Return vs Market: B9A underperformed the German Market which returned 2.3% over the past year.

Price Volatility

Is B9A's price volatile compared to industry and market?
B9A volatility
B9A Average Weekly Movement	6.9%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: B9A's share price has been volatile over the past 3 months.

Volatility Over Time: B9A's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2000	88	n/a	www.bioarctic.se

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.

BioArctic AB (publ) Fundamentals Summary

How do BioArctic's earnings and revenue compare to its market cap?
B9A fundamental statistics
Market cap	€1.46b
Earnings (TTM)	€19.63m
Revenue (TTM)	€52.74m

74.6x

P/E Ratio

27.8x

P/S Ratio

Is B9A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B9A income statement (TTM)
Revenue	kr616.00m
Cost of Revenue	kr89.63m
Gross Profit	kr526.37m
Other Expenses	kr297.12m
Earnings	kr229.25m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 17, 2024

Earnings per share (EPS)	2.60
Gross Margin	85.45%
Net Profit Margin	37.22%
Debt/Equity Ratio	0%

How did B9A perform over the long term?

See historical performance and comparison

B9A Stock Overview

Rewards

Risk Analysis

BioArctic AB (publ) Competitors

XTRA:BIO3

€1.4b

XTRA:DMP

€1.7b

NasdaqGS:KNSA

US$1.2b

CPSE:BAVA

kr.11.2b

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Third quarter 2023 earnings released: EPS: kr1.42 (vs kr1.55 in 3Q 2022)

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

Recent updates

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Third quarter 2023 earnings released: EPS: kr1.42 (vs kr1.55 in 3Q 2022)

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold €242k worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

New minor risk - Share price stability

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Now 21% undervalued

Vice President of Communications & IR recently sold €147k worth of stock

BioArctic AB (publ) Approves Board Changes

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold €575k worth of stock

Insider recently bought €21k worth of stock

First quarter 2023 earnings released

Independent Director recently sold €291k worth of stock

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Second quarter 2022 earnings released: kr0.52 loss per share (vs kr0.39 loss in 2Q 2021)

Independent Director recently bought €54k worth of stock

First quarter 2022 earnings released

Insufficient new directors

Full year 2021 earnings released: kr1.36 loss per share (vs kr0.78 loss in FY 2020)

Independent Deputy Chairman recently bought €78k worth of stock

Bioarctic AB Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioArctic AB (publ) to Report Fiscal Year 2021 Final Results on Mar 31, 2022

DIAN-TU Enrolls First Subject for the Tau Nexgen Study with Lecanemab as Back-Ground Anti-Amyloid Treatment

Bioarctic AB (Publ) Announces Lecanemab Granted Fast Track Designation by the FDA

Third quarter 2021 earnings released

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

Chief Medical Officer recently bought €10k worth of stock

Chief Medical Officer recently bought €10k worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease

Independent Director has left the company

First quarter 2021 earnings released: kr0.33 loss per share (vs kr0.04 profit in 1Q 2020)

Bioarctic and Eisai Present Latest Data Regarding Lecanemab at AD/PD 2021

Bioarctic AB (Publ) and Eisai to Present Data Relating to Its Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody Lecanemab (BAN2401)

BioArctic AB (publ) Announces Board Changes

Full year 2020 earnings released: kr0.78 loss per share (vs kr1.01 profit in FY 2019)

Revenue beats expectations

BioArctic AB (publ) to Report Fiscal Year 2020 Final Results on Mar 31, 2021

BioArctic AB Increases the Number of Participants in Clarity AD Study